Nisha Venugopal

Nisha Venugopal

Auto-generated profile, based on publicly available information

Nisha Venugopal

Institute of Bioinformatics and Applied Biotechnology

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2020 in BMC Molecular and Cell Biology
Verified
Journal Article
Open access
PDF file
NVNisha Venugopal
Nisha Venugopal
AGAnanga Ghosh
Ananga Ghosh
HGHardik Gala
Hardik Gala
AAAjoy Aloysius
Ajoy Aloysius
NVNeha Vyas
Neha Vyas
JDJyotsna Dhawan
Jyotsna Dhawan
Background: Reversible cell cycle arrest (quiescence/G0) is characteristic of adult stem cells and is actively controlled at multiple levels. Quiescent cells also extend a primary cilium, which functions as a signaling hub. Primary cilia have been shown to be important in multiple developmental processes, and are implicated in numerous developmental disorders. Although the association of the cilium with G0 is established, the role of the cilium in the control of the quiescence program is still poorly understood. Results: Primary cilia are dynamically regulated across different states of cell cycle exit in skeletal muscle myoblasts: quiescent myoblasts elaborate a primary cilium in vivo and in vitro, but terminally differentiated myofibers do not. Myoblasts where ciliogenesis is ablated using RNAi against a key ciliary assembly protein (IFT88) can exit the cell cycle but display an altered quiescence program and impaired self-renewal. Specifically, the G0 transcriptome in IFT88 knockdown cells is aberrantly enriched for G2/M regulators, suggesting a focused repression of this network by the cilium. Cilium-ablated cells also exhibit features of activation including enhanced activity of Wnt and mitogen signaling and elevated protein synthesis via inactivation of the translational repressor 4E-BP1. Conclusions: Taken together, our results show that the primary cilium integrates and dampens proliferative signaling, represses translation and G2/M genes, and is integral to the establishment of the quiescence program.

1 March 2017
Verified
Book Chapter
Open access
PDF file
RAReety Arora
Reety Arora
MRMohammed Rumman
Mohammed Rumman
NVNisha Venugopal
Nisha Venugopal
HGHardik Gala
Hardik Gala
JDJyotsna Dhawan
Jyotsna Dhawan
Growing evidence supports the view that in adult stem cells, the defining stem cell features of potency and self-renewal are associated with the quiescent state. Thus, uncovering the molecular logic of this reversibly arrested state underlies not only a fundamental understanding of adult tissue dynamics but also hopes for therapeutic regeneration and rejuvenation of damaged or aging tissue. A key question concerns how adult stem cells use quiescence to establish or reinforce the property of self-renewal. Since self-renewal is largely studied by assays that measure proliferation, the concept of self-renewal programs imposed during non-proliferating conditions is counterintuitive. However, there is increasing evidence generated by deconstructing the quiescent state that highlights how programs characteristic of this particular cell cycle exit may enhance stem cell capabilities, through both cell-intrinsic and extrinsic programs. Toward this end, culture models that recapitulate key aspects of stem cell quiescence are useful for molecular analysis to explore attributes and regulation of the quiescent state. In this chapter, we review the different methods used to generate homogeneous populations of quiescent muscle cells, largely by manipulating culture conditions that feed into core signaling programs that regulate the cell cycle. We also provide detailed protocols developed or refined in our lab over the past two decades.

1 August 2022 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
HGHardik P. Gala
Hardik P. Gala
DSDebarya Saha
Debarya Saha
NVNisha Venugopal
Nisha Venugopal
AAAjoy Aloysius
Ajoy Aloysius
GPGunjan Purohit
Gunjan Purohit
JDJyotsna Dhawan
Jyotsna Dhawan
Adult stem cells persist in mammalian tissues by entering a state of reversible quiescence, referred to as G0, which is associated with low levels of transcription. Using cultured myoblasts and muscle stem cells, we report that in G0, global RNA content and synthesis are substantially repressed, correlating with decreased RNA polymerase II (RNAPII) expression and activation. Integrating RNAPII occupancy and transcriptome profiling, we identify repressed networks and a role for promoter-proximal RNAPII pausing in G0. Strikingly, RNAPII shows enhanced pausing in G0 on repressed genes encoding regulators of RNA biogenesis (such as Ncl, Rps24, Ctdp1), and release of pausing is associated with increased expression of these genes in G1. Knockdown of these transcripts in proliferating cells leads to induction of G0 markers, confirming the importance of their repression in establishment of G0. A targeted screen of RNAPII regulators revealed that knockdown of Aff4 (a positive regulator of elongation) unexpectedly enhances expression of G0-stalled genes and hastens S phase; however, the negative elongation factor (NELF) complex, a regulator of pausing, appears to be dispensable. We propose that RNAPII pausing contributes to transcriptional control of a subset of G0-repressed genes to maintain quiescence and impacts the timing of the G0-G1 transition. This article has an associated First Person interview with the first authors of the paper.

1 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LMLavanyaa Manjunatha
Lavanyaa Manjunatha
MSM Saundarya
M Saundarya
DDDeepika Dokuru
Deepika Dokuru
NVNisha Venugopal
Nisha Venugopal
JWJenifer Ngo Waldrop
Jenifer Ngo Waldrop
HRHarsha K Rajasimha
Harsha K Rajasimha
Background: Addressing inequities and health disparities for medically underserved populations (MUPs) is critical, as they already face systemic bias and barriers, such as historical mistrust of healthcare systems. To achieve health equity, we need systematic approaches to measuring, quantifying, and reporting diversity, equity, inclusion, and accessibility (DEIA) metrics. Methods: The objective of the study was to analyze literature and clinical trials to summarize the current state of demographics and socioeconomic factors (SF) reporting for MUPs in US-based RD clinical research. PubMed, Cochrane Library, and ClinicalTrials.gov were searched (1983– 2023). A universal set of 30,303 unique RD terms from the Genetic and Rare Diseases Information Center, Orphanet, Rare-X, and ClinicalTrials.gov was used to filter publications and clinical trials. Publications that reported demographics or SFs, were US-based, and involved one or more RDs were included for analysis. Clinical trials that were US-based, involved an RD, and had study results posted were also included. Age, sex or gender, race, ethnicity, and SF data were extracted and analyzed using descriptive statistics. Race and ethnicity data were compared with the US census. The representation of MUPs in RD clinical research was assessed based on the frequency of publications and clinical trials reporting 13 variables. Results: We reviewed 234 publications and 8475 RD clinical trials. Age was the most reported demographic variable (publications: 94%; clinical trials: 100%), followed by sex or gender (86.3%; 100%). Race (50%; 45.7%) and ethnicity (29.9%; 38.5%) were less frequently reported and often in a variable format in publications compared with the ClinicalTrials.gov database. At least one SF was reported in 15.8% of the publications and 0.2% of the trials. American Indian or Native Alaskan, Asian, Hispanic, and Latino participants were significantly underrepresented compared with the US census averages. Data were largely absent for other MUPs: lesbian, gay, bisexual, transgender, and queer or questioning individuals, rural residents, veterans, immigrants, and those affected by disability and poverty. Conclusions: Significant gaps exist in demographics and SF reporting in RD clinical research, and several MUPs are underrepresented. Therefore, a framework to enhance DEIA in RD research is urgently needed.

8 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LMLavanyaa Manjunatha
Lavanyaa Manjunatha
MSM Saundarya
M Saundarya
NVNisha Venugopal
Nisha Venugopal
JWJenifer Ngo Waldrop
Jenifer Ngo Waldrop
LBLinda Goler Blount
Linda Goler Blount
HRHarsha K Rajasimha
Harsha K Rajasimha
Background: Equitable representation of all populations is crucial for generalizing rare disease (RD) clinical research outcomes, especially given the low prevalence and geographically sparse distribution of patients with RDs. In our companion manuscript ( Current State and Demographic Trends of Medically Underserved Populations in Rare Disease Research , Manjunatha et al. ) we quantified reporting of demographics, socioeconomic factors (SF), and participation trends of medically underserved populations (MUPs) in RD research and clinical trials. Methods: The study builds on the findings of Manjunatha et al ., where we analyzed the reporting of demographics and SF in RD clinical research, here we perform a representation and policy gap analysis of this extracted data. The representation analysis evaluated 13 variables, including age, sex or gender, race, ethnicity, and SF, using four key analyses: reporting statistics, representation, participant distribution, and benchmarking against the US census data. The qualitative policy analysis included existing national and international policies and guidelines. Results: Only age, sex or gender, race, and ethnicity had sufficient data for the representation analysis. While diversity was moderate for these variables, equity, inclusion, and accessibility were low, particularly for racial and ethnic minorities, nonbinary genders, and older adults. Data were insufficient for MUPs such as lesbian, gay, bisexual, transgender, queer or questioning individuals, rural residents, veterans, military spouses, people affected by poverty, and religious minorities. Based on the representation analysis and building upon existing foundational policies and guidelines, we propose three recommendations and a six-pillar framework to mandate and standardize data reporting practices and improve the representation of MUPs in RD clinical research with broader relevance to all clinical research in general. The six pillars are patient advocacy, policy legislation, governmental oversight, standardized data collection and reporting, technological enablement, and global epidemiological research. Conclusions: Addressing the historical underrepresentation of MUPs requires upgrading the foundation of clinical research instead of a piecemeal, siloed approach. This study underscores the systemic gaps in the representation of MUPs in RD research and proposes a six-pillar actionable framework to address these disparities. The systematic implementation of these six pillars can enhance the integrity and outcomes of future RD clinical research.

6 December 2019 in Research Square
Verified
Preprint
Open access
NVNisha Venugopal
Nisha Venugopal
AGAnanga Ghosh
Ananga Ghosh
HGHardik Gala
Hardik Gala
AAAjoy Aloysius
Ajoy Aloysius
NVNeha Vyas
Neha Vyas
JDJyotsna Dhawan
Jyotsna Dhawan
Background: Reversible cell cycle arrest (quiescence/G0) is characteristic of adult stem cells and is actively controlled at multiple levels. Quiescent cells also extend a primary cilium, which functions as a signaling hub. Primary cilia have been shown to be important in multiple developmental processes, and are implicated in numerous developmental disorders. Although the association of the cilium with G0 is established, the role of the cilium in the control of the quiescence program is still poorly understood.Results: Primary cilia are dynamically regulated across different states of cell cycle exit in skeletal muscle myoblasts: quiescent myoblasts elaborate a primary cilium in vivo and in vitro , but terminally differentiated myofibers do not. Myoblasts where ciliogenesis is ablated using RNAi against a key ciliary assembly protein (IFT88) can exit the cell cycle but display an altered quiescence program and impaired self-renewal. Specifically, the G0 transcriptome in IFT88 knockdown cells is aberrantly enriched for G2/M regulators, suggesting a focused repression of this network by the cilium. Cilium-ablated cells also exhibit features of activation including enhanced activity of Wnt and mitogen signaling and elevated protein synthesis via inactivation of the translational repressor 4E-BP1.Conclusions: Taken together, our results show that the primary cilium integrates and dampens proliferative signaling, represses translation and G2/M genes, and is integral to the establishment of the quiescence program.